Last reviewed · How we verify
Reslizumab SC
At a glance
| Generic name | Reslizumab SC |
|---|---|
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents (PHASE2)
- Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists (PHASE1)
- A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma (PHASE3)
- An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils (PHASE3)
- Absolute Bioavailability of Reslizumab in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reslizumab SC CI brief — competitive landscape report
- Reslizumab SC updates RSS · CI watch RSS
- Teva Branded Pharmaceutical Products R&D, Inc. portfolio CI